Rankings
▼
Calendar
ALNY FY 2017 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
FY 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$90M
+90.7% YoY
Gross Profit
$77M
85.1% margin
Operating Income
-$500M
-556.2% margin
Net Income
-$491M
-545.9% margin
EPS (Diluted)
$-5.42
Cash Flow
Operating Cash Flow
-$383M
Free Cash Flow
-$487M
Stock-Based Comp.
$93M
Balance Sheet
Total Assets
$2.0B
Total Liabilities
$228M
Stockholders' Equity
$1.8B
Cash & Equivalents
$645M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$90M
$47M
+90.7%
Gross Profit
$77M
$47M
+62.3%
Operating Income
-$500M
-$425M
-17.8%
Net Income
-$491M
-$410M
-19.7%
← Q4 2016
All Quarters
Q1 2017 →